Evidence map›Paper›PMID 40213945›Full record

ArticleeLife2025

Loss function of tumor suppressor FRMD8 confers resistance to tamoxifen therapy via a dual mechanism.

Weijie Wu, Miao Yu, Qianchen Li, Yiqian Zhao, Lei Zhang, Yi Sun, Zhenbin Wang, Yuqing Gong, Wenjing Wang, Chenying Liu and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in eLife, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Weijie Wu *Program for Cancer and Cell Biology, Department of Human Anatomy, Histology and Embryology, School of Basic Medical Sciences, Peking University International Cancer Institute, State Key Laboratory of Molecular Oncology, Peking University Health Science Center, Beijing, China.ORCID https://orcid.org/0009-0001-4621-7243
Miao Yu *Program for Cancer and Cell Biology, Department of Human Anatomy, Histology and Embryology, School of Basic Medical Sciences, Peking University International Cancer Institute, State Key Laboratory of Molecular Oncology, Peking University Health Science Center, Beijing, China.ORCID https://orcid.org/0000-0002-2256-0231
Qianchen LiProgram for Cancer and Cell Biology, Department of Human Anatomy, Histology and Embryology, School of Basic Medical Sciences, Peking University International Cancer Institute, State Key Laboratory of Molecular Oncology, Peking University Health Science Center, Beijing, China.
Yiqian ZhaoProgram for Cancer and Cell Biology, Department of Human Anatomy, Histology and Embryology, School of Basic Medical Sciences, Peking University International Cancer Institute, State Key Laboratory of Molecular Oncology, Peking University Health Science Center, Beijing, China.
Lei ZhangProgram for Cancer and Cell Biology, Department of Human Anatomy, Histology and Embryology, School of Basic Medical Sciences, Peking University International Cancer Institute, State Key Laboratory of Molecular Oncology, Peking University Health Science Center, Beijing, China.
Yi SunProgram for Cancer and Cell Biology, Department of Human Anatomy, Histology and Embryology, School of Basic Medical Sciences, Peking University International Cancer Institute, State Key Laboratory of Molecular Oncology, Peking University Health Science Center, Beijing, China.
Zhenbin WangProgram for Cancer and Cell Biology, Department of Human Anatomy, Histology and Embryology, School of Basic Medical Sciences, Peking University International Cancer Institute, State Key Laboratory of Molecular Oncology, Peking University Health Science Center, Beijing, China.
Yuqing GongProgram for Cancer and Cell Biology, Department of Human Anatomy, Histology and Embryology, School of Basic Medical Sciences, Peking University International Cancer Institute, State Key Laboratory of Molecular Oncology, Peking University Health Science Center, Beijing, China.
Wenjing WangDepartment of Gastroenterology, Beijing Friendship Hospital, Capital Medical University; State Key Laboratory for Digestive Health; National Clinical Research Center for Digestive Diseases, Beijing, China.
Chenying LiuDepartment of Breast Pathology and Lab, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy of Ministry of Education of China, Tianjin Medical University, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Jing ZhangProgram for Cancer and Cell Biology, Department of Human Anatomy, Histology and Embryology, School of Basic Medical Sciences, Peking University International Cancer Institute, State Key Laboratory of Molecular Oncology, Peking University Health Science Center, Beijing, China.
Yan TangProgram for Cancer and Cell Biology, Department of Human Anatomy, Histology and Embryology, School of Basic Medical Sciences, Peking University International Cancer Institute, State Key Laboratory of Molecular Oncology, Peking University Health Science Center, Beijing, China.
Xiaojie XuDepartment of Genetic Engineering, Beijing Institute of Biotechnology, Beijing, China.
Xiaojing GuoDepartment of Breast Pathology and Lab, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy of Ministry of Education of China, Tianjin Medical University, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Jun ZhanProgram for Cancer and Cell Biology, Department of Human Anatomy, Histology and Embryology, School of Basic Medical Sciences, Peking University International Cancer Institute, State Key Laboratory of Molecular Oncology, Peking University Health Science Center, Beijing, China.
Hongquan ZhangProgram for Cancer and Cell Biology, Department of Human Anatomy, Histology and Embryology, School of Basic Medical Sciences, Peking University International Cancer Institute, State Key Laboratory of Molecular Oncology, Peking University Health Science Center, Beijing, China.ORCID https://orcid.org/0000-0001-8193-0899

Funding

Ministry of Science and Technology of the People's Republic of China 2021YFC2501000Ministry of Science and Technology of the People's Republic of China 2022YFA1104003National Natural Science Foundation of China 81772840National Natural Science Foundation of China 81972609National Natural Science Foundation of China 81972616National Natural Science Foundation of China 82172972National Natural Science Foundation of China 82230094Peking University Health Science Center BMU2024YFJHPY004Postdoctoral Fellowship Program of CPSF GZC20230159
6 · The paper itself

Abstract

Approximately 40% ERα-positive breast cancer patients suffer from therapeutic resistance to tamoxifen. Although reduced ERα level is the major cause of tamoxifen resistance, the underlying mechanisms remain elusive. Here, we report that FRMD8 raises the level of ERα at both transcriptional and post-translational layers. FRMD8 deficiency in

Indexed as

Antineoplastic Agents, HormonalBreast NeoplasmsDrug Resistance, NeoplasmTamoxifenAnimalsEstrogen Receptor alphaFemaleGene Expression Regulation, NeoplasticHumansMiceAntineoplastic Agents, HormonalEstrogen Receptor alphaTamoxifenbreast cancercancer biologyERαFRMD8humanmousetamoxifen resistanceUBE3A

Identifiers

PMID40213945
PMCPMC11991697

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.